The Latest Cardiac and Vascular News
Additional funding brings Series D round to $320M total Trevor Fetter, MBA, senior lecturer on the faculty of Harvard Business School and former longtime Tenet Healthcare chairman and CEO, named to Board Sachin H. Jain, physician executive with government, pharmaceutical, payer and provider experience, […]
Biofourmis Care, a comprehensive care management platform including virtual multidisciplinary care teams, to be evaluated against in-person care among underserved patients with chronic cardiovascular conditions BOSTON, May 12, 2022 /PRNewswire/ — Biofourmis, a Boston-based global leader in virtual care and digital medicine, announced today […]
First of its kind service combines a specialized, multidisciplinary clinical care team with an AI-enabled care management platform for automated medication management, earlier interventions and improved outcomes BOSTON, Feb. 9, 2022 /PRNewswire/ — Biofourmis, a Boston-based global leader in virtual care and digital therapeutics, […]
BiovitalsHF® Approved for Expedited FDA Review Process as a First-in-Class DTx for Heart Failure that Augments Traditional Guideline-Directed Medical Therapy BOSTON, July 29, 2021 /PRNewswire/ — Biofourmis, a Boston-based global leader in virtual care and digital therapeutics, announced today its BiovitalsHF® solution is the […]
Funding to advance “home hospital” initiatives with health systems and “beyond the pill” digital therapeutics partnerships with pharmaceutical companies BOSTON, Sept. 3, 2020 /PRNewswire/ — Biofourmis, a fast-growing global leader in digital therapeutics that powers personalized predictive care, has announced the completion of […]
Finance leader Matt Borowiecki brings deep M&A and fundraising experience to his new role BOSTON, May 26, 2020 /PRNewswire/ — Biofourmis, a fast-growing global leader in digital therapeutics that powers personally predictive care, has named Matt Borowiecki its Chief Financial Officer (CFO) to enhance decision-making […]
Biofourmis’ artificial intelligence-powered RhythmAnalytics® to provide clinical decision support that IDs cardiac arrhythmias and other issues requiring intervention BOSTON, Jan. 30, 2020 /PRNewswire/ — Biofourmis, a fast-growing global leader in digital therapeutics that powers personally predictive care, and ImagineMIC™ announced a partnership agreement […]
BOSTON, July 16, 2019 /PRNewswire/ — Biofourmis, a fast-growing global leader in digital therapeutics, has entered a research partnership with the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI). Biofourmis’ mobile platform BiovitalsHFTM will be leveraged in a study of patients with […]
BOSTON, April 30, 2019 /PRNewswire/ — Biofourmis announced today that the U.S. Food and Drug Administration (FDA) has granted the company clearance for its RhythmAnalyticsTM platform, a cloud-based software for automated interpretation of cardiac arrhythmias. It uses an enhanced deep-learning technique to detect over 15 […]
